Emmecell Doses First Patient in EMERALD Study for Magnetic Cell Therapy to Treat Corneal Endothelial Disease in U.S.
Rapid Read

Emmecell Doses First Patient in EMERALD Study for Magnetic Cell Therapy to Treat Corneal Endothelial Disease in U.S.

What's Happening? Emmecell, a clinical-stage biotechnology company, has announced that the first patient has been dosed in its EMERALD study (NCT07729137). This Phase 2 clinical trial, conducted in the United States, is evaluating EO2002, an investigational magnetic cell therapy for adults with corn
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.